Skip to main content
Top
Published in: Metabolic Brain Disease 3/2022

01-03-2022 | Neuroblastoma | Original Article

Sesamol prevents mitochondrial impairment and pro-inflammatory alterations in the human neuroblastoma SH-SY5Y cells: role for Nrf2

Authors: Sônia Mendes da Silva Navarro, Fhelipe Jolner Souza de Almeida, Matheus Dargesso Luckachaki, Marcos Roberto de Oliveira

Published in: Metabolic Brain Disease | Issue 3/2022

Login to get access

Abstract

Mitochondria are a primary source and a target of reactive oxygen species (ROS). Increased mitochondrial production of ROS is associated with bioenergetics decline, cell death, and inflammation. Here we investigated whether a pretreatment (for 24 h) with sesamol (SES; at 12.5—50 µM) would be efficient in preventing the mitochondrial collapse induced by hydrogen peroxide (H2O2, at 300 µM) in the human neuroblastoma SH-SY5Y cell line. We have found that a pretreatment with SES at 25 µM decreased the effects of H2O2 on lipid peroxidation, protein carbonylation, and protein nitration in membranes obtained from the mitochondria isolated from the SH-SY5Y cells. In this regard, SES pretreatment decreased the production of superoxide anion radical (O2−•) by the mitochondria of H2O2-treated cells. SES also prevented the mitochondrial dysfunction induced by H2O2, as assessed by analyzing the activity of the complexes I and V. The H2O2-induced reduction in the production of adenosine triphosphate (ATP) was also prevented by SES. The levels of the pro-inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), as well as the activity of the transcription factor nuclear factor-κB (NF-κB) were downregulated by the SES pretreatment in the H2O2-challenged cells. Silencing of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor abolished the protection induced by SES regarding mitochondrial function and inflammation. Thus, SES depends on Nrf2 to promote mitochondrial protection in cells facing redox impairment.
Appendix
Available only for authorised users
Literature
go back to reference VanGilder RL, Huber JD (2014) Sesamol: a treatment for diabetes-associated blood-brain barrier dysfunction. Postdoc J 2:13–22PubMedPubMedCentral VanGilder RL, Huber JD (2014) Sesamol: a treatment for diabetes-associated blood-brain barrier dysfunction. Postdoc J 2:13–22PubMedPubMedCentral
Metadata
Title
Sesamol prevents mitochondrial impairment and pro-inflammatory alterations in the human neuroblastoma SH-SY5Y cells: role for Nrf2
Authors
Sônia Mendes da Silva Navarro
Fhelipe Jolner Souza de Almeida
Matheus Dargesso Luckachaki
Marcos Roberto de Oliveira
Publication date
01-03-2022
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 3/2022
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-021-00875-5

Other articles of this Issue 3/2022

Metabolic Brain Disease 3/2022 Go to the issue